Advertisement

Annals of Surgical Oncology

, Volume 18, Supplement 3, pp 286–287 | Cite as

Strategy for Nonresponder Breast Cancer Patients to Neoadjuvant Treatment

Breast Oncology
  • 72 Downloads

Keywords

Breast Cancer Trastuzumab Oncological Outcome Inflammatory Breast Cancer Breast Cancer Experience 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, et al. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011;18:932–8.PubMedCrossRefGoogle Scholar
  2. 2.
    de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467:543–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 2011;11:81–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med. 2010;4(4):583–6. No abstract available.PubMedCrossRefGoogle Scholar
  6. 6.
    Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn. 2010;10(5):541–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics. 2010;11(8):1039–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Roukos DH. Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices. 2011;8(4):409–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH. Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics. 2011;12(5):695–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Roukos DH. Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices. 2011;8(2):123–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Roukos DH. Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol. 2011;18(1):12–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices. 2010;7(6):723–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Personal Med. 2010;7(4):347–50.CrossRefGoogle Scholar
  14. 14.
    Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther. 2010;10(2):123–8.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  1. 1.Department of SurgeryUniversity Hospital of Ioannina, School of MedicineIoanninaGreece

Personalised recommendations